Acute obstructive pyelonephritis (AOP) is a urological life-threatening inflammatory condition that initially requires immediate urinary drainage and simultaneous prescribing of highly effective targeted antibacterial treatment. The empirical antibacterial therapy is always prescribed before urine culture and susceptibility testing are done. Percutaneous nephrostomy (PNS) and ureteral stenting (US) are the two options for urinary drainage in obstructed kidneys, while fluoroquinolones and 3(rd) generation cephalosporins are the main groups of antibacterial drugs that are recommended and are available for empirical AOP therapy. In our study we aimed to compare efficacy of fluoroquinolone ciprofloxacin vs 3(rd) generation cephalosporin ceftazidime in empirical antibacterial treatment of patients with acute obstructive pyelonephritis. We also tried to analyze the impact of urinary drainage option on cure rates. 241 AOP patients were randomized into two groups: Group 1, n=124 pts in whom percutaneous nephrostomy was performed urinary drainage and Group 2, n=117 pts, in whom ureteral stenting was made. Then each abovementioned group was also randomized into equal two subgroups (ciprofloxacin vs ceftazidime) depending on the empiric antibacterial treatment which was chosen. Our results revealed that cure rates in patients treated by ceftazidime were higher than those who were treated by ciprofloxacin. At late follow-up, the clinical cure rate in PNS group treated by ceftazidime was 95.2% vs 83.6% in ciprofloxacin arm, while the microbiological cure rates were 92.9% vs 80.0% correspondingly (p<0.05). At late follow-up, the clinical cure rate in US group treated by ceftazidime was 86.4% vs 74.1% in ciprofloxacin arm while the microbiological cure rates were 82.4% vs 69.4% correspondingly (p<0.05). We also concluded that percutaneous nephrostomy ensures a better clinical cure than ureteral stenting at early and late follow-ups regardless of the drug regimes which were chosen. Thus, in our opinion, percutaneous nephrostomy combined with ceftazidime treatment can be considered as the most effective option in patients with acute obstructive pyelonephritis.

No abstract

Gestational pyelonephritis (GP) is one of the most frequent and serious diseases of the middle and second half of pregnancy, which complicates about 6% of pregnancies and is one of the leading causes of non-obstetric prenatal hospitalization. The objective: was to improve the treatment of GP with phytopreparation Canephron® N. Materials and methods. The paper provides data from the open, multicentre, prospective, comparative (parallel group) study in 60 pregnant women diagnosed with gestational pyelonephritis, which were divided into two groups 30 subjects each. Patients in the treatment group received antibacterial therapy for 7 days + treatment with standard dosage of medicinal product Canephron® N for 3 months. Patients in the control group received antibiotic therapy alone for 7 days. Results. The average age of pregnant women at the time of diagnosing was 23±6.23 years; it was the first pregnancy for 39 women (65 %). The most common complaints at admission to the in-patient department were as follows: lumbar pain (96.2 %), dysuria (70.2 %), rise in temperature above 38°C (64.4 %). Leukocyturia and bacteriuria were detected in 100 % of cases with prevalence of E. coli in 84.2 % (101 of 120) of cases. By 30 day in GP patients in the treatment group bacteriuria was detected in 2/30 (6.67 %) patients, and in the control group – in 5/30 (16.7 %) patients (p 1: 2 <0.05), by 60 day in the treatment group – 2/30 (6.67 %), in the control group – 8/30 (26.7 %) (p 1: 2 <0.05), respectively, by 90 day – 3/30 (10 %) and 10 (33.3 %), respectively (p 1: 2 <0.05). The disease relapsed in 1 of 30 (3.33 %) GP patients in the treatment group and 3/30 (10 %) patients in the control group (p 1: 2 <0.05) and 3/30 (10 %) patients in the treatment group with CP, and 7/30 (23.3 %) patients in the control group during the follow-up period (p 1: 2 <0.05). Conclusion. The use of the herbal medicinal product Canephron® N in pregnant women with gestational pyelonephritis and in the acute exacerbations of chronic pyelonephritis has shown its high efficacy and undoubted therapeutic and prophylactic effect, good tolerability and decrease in the frequency of relapses of pyelonephritis. Key words: gestational pyelonephritis, pregnancy, Canephron® N, leukocyturia, bacteriuria, urosepsis, kidney, infection, urinary tract.

No abstract